Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The inspections concluded with no Form 483 observations or significant critical findings
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Subscribe To Our Newsletter & Stay Updated